WILMINGTON, Del., October 15, 2026
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company focused on developing therapies for depression, post-traumatic stress disorder (PTSD) and related conditions, announced that it has received a Discipline Review Letter from the U.S. Food and Drug Administration (FDA) requesting minor changes to the proposed labeling for its preservative-free ketamine product. The letter was issued ahead of the November 10, 2026, Generic Drug User Fee Amendments (GDUFA) goal date for the company’s Abbreviated New Drug Application (ANDA). According to NRx, all requested labeling changes were classified as “MINOR.” The FDA also requested sample labeling that includes the proprietary product name currently under agency review. NRx said it is completing final manufacturing process validation runs to meet product launch requirements. The announcement marks a further step in the regulatory review of the company’s preservative-free intravenous ketamine product, designated NRX-100. However, the labeling review letter does not itself constitute FDA approval, and the product’s regulatory status will depend on completion of the applicable review process. NRx said it appreciates the FDA’s engagement as it works toward the upcoming regulatory milestone and aims to establish U.S.-based manufacturing for the product.
FDA Requests Minor Labeling Changes Ahead of GDUFA Date
The FDA’s Discipline Review Letter addresses the proposed labeling submitted for NRx Pharmaceuticals’ preservative-free ketamine product. The company reported that the agency classified all requested changes as minor and asked NRx to submit sample labels incorporating the proprietary name currently under review. The request comes ahead of the November 10, 2026, GDUFA goal date associated with the ANDA. NRx said it is preparing the requested labeling materials as the review progresses. A GDUFA goal date is a target for the FDA’s review action, rather than a guarantee of approval by that date. The announcement did not provide details of the individual labeling revisions or confirm that the agency had completed its review. The proprietary product name also remains under FDA review, according to the company. NRx Chairman and Chief Executive Officer Jonathan Javitt, M.D., MPH, welcomed the agency’s engagement and said the company looks forward to demonstrating that manufacturing medicines such as ketamine can be brought back to the United States. The next regulatory steps will include addressing the agency’s labeling request and completing the remaining requirements associated with the application.
Manufacturing Validation Progresses Toward Potential Launch
Alongside the regulatory review, NRx reported that it is completing final manufacturing process validation runs for its preservative-free ketamine product. Process validation is intended to demonstrate that a manufacturing process can consistently produce a product meeting established quality requirements. The company said this work is part of its preparation to meet product launch requirements. NRx also highlighted the importance of domestic production, noting that U.S. supplies of ketamine have relied substantially on overseas manufacturing and that hospitals and physicians have experienced repeated shortages. The company’s stated objective is to support U.S.-based manufacturing of a preservative-free preparation. However, the announcement did not provide a confirmed commercial launch date, production capacity, pricing details or a final FDA decision. Completion of manufacturing validation and resolution of regulatory requirements will be important milestones as the company advances the product toward potential market availability. The preservative-free formulation is the focus of this announcement; the company did not report new clinical efficacy results or changes to the product’s proposed clinical use in the release.
Advertisement
NRX-100 Anchors NRx’s CNS Development Pipeline
NRx Pharmaceuticals is developing therapies based on its NMDA receptor platform for central nervous system disorders, including suicidal depression, chronic pain and PTSD. Its pipeline includes NRX-100, the company’s preservative-free intravenous ketamine product, and NRX-101, an oral combination of D-cycloserine and lurasidone. According to the company, NRX-100 has received FDA Fast Track designation for suicidal ideation in depression, including bipolar depression, while NRX-101 has received Breakthrough Therapy designation for suicidal bipolar depression. These designations support development and regulatory interactions but do not establish that a product is approved or proven effective for the relevant indication. NRx stated that it has filed an ANDA and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. The current labeling review letter relates to the preservative-free ketamine product and its ANDA review. The company’s immediate priorities include responding to the FDA’s request for sample labeling, completing manufacturing process validation and progressing through the regulatory review. The FDA’s final action and the timing of any potential launch remain subject to the ongoing review process.
Source:::NRx Pharmaceuticals,,,press release
